Recombinant Human MELK (1-340aa) (N-GST tag)
Catalog No : IGX-RP919
366.40€
0.00€
Shipping cost plus VAT not included , delivery in 7-14 business days
| Product name | Recombinant Human MELK (1-340aa) (N-GST tag) | ||
|---|---|---|---|
| Catalog No | IGX-RP919 | ||
| Supplier’s Catalog No | IGX-RP919 | ||
| Supplier | ImuGeX | ||
| Source antigen | Insect cells | ||
| Reactivity | Human | ||
| Cross reactivity | |||
| Applications | |||
| Molecular weight | 61 | ||
| Storage | -70°C | ||
|---|---|---|---|
| Other names | HPK38, KIAA0175 | ||
| Grade | Highly Purified | ||
| Purity | 70% - 90% | ||
| Form | 50mM Tris-HCl, pH 7.5, 150mM NaCl, 10mM glutathione, 0.1mM EDTA, 0.25mM DTT, 0.1mM PMSF, 25% glycerol. | ||
| Reactivity life | 6 months | ||
| Note | For reserch purpose only | ||
| Purity | 70% - 90% | ||
| Description | MELK or maternal embryonic leucine zipper kinase is a member of the CAMKL kinase family. MELK is a key regulator of the proliferation of malignant brain tumors including their stem cells . MELK transcript abundance correlates with malignancy grade in human astrocytomas and represents a therapeutic target for the management of the most frequent brain tumors in adult and children. MELK also plays a role in mammary carcinogenesis through inhibition of the pro-apoptotic function of Bcl-GL . Therefore, the kinase activity of MELK could be a promising molecular target for development of therapy for patients with breast cancers. | ||
Product Details
© 2020 Imugex All Rights Reserved